natgillin/translations-raw huggingface dataset:
In vitro undersøgelser har vist at LeukoScan ikke har nogen virkning på hverken op- eller nedregulering af granulocyter, men LeukoScan ser ud til at bindes stærkere til aktiverede end til hvilende granulocyter.
In vitro studies have demonstrated that LeukoScan has no effect on either up-regulation or down- regulation of granulocytes, but LeukoScan does appear to bind more avidly to activated rather than resting granulocytes.
In vitro undersøgelser har vist, at aclidiniumbromid eller dets metabolitter ved den terapeutiske dosis ikke forventes at forårsage interaktioner med P-glykoprotein (P-gp) substrat-lægemidler eller lægemidler metaboliseret af cytokrom P450 (CYP450) -enzymer og esteraser.
In vitro studies have shown that aclidinium or its metabolites at the therapeutic dose are not expected to cause interactions with P-glycoprotein (P-gp) substrate drugs or drugs metabolised by cytochrome P450 (CYP450) enzymes and esterases.
In vitro undersøgelser har vist, at aclidiniumbromid eller metabolitterne af aclidiniumbromid ved den terapeutiske dosis ikke forventes at forårsage interaktioner med P-glykoprotein (P-gp) substrat- lægemidler eller lægemidler metaboliseret af cytochrom P450 (CYP450) -enzymer og esteraser (se pkt.
In vitro studies have shown that aclidinium bromide or the metabolites of aclidinium bromide at the therapeutic dose are not expected to cause interactions with P-glycoprotein (P-gp) substrate drugs or drugs metabolised by cytochrome P450 (CYP450) enzymes and esterases (see section 5.2).
In vitro undersøgelser med humane levermikrosomer har vist at cytokrom CYP3A4 er det eneste P450 isozym, som spiller en større rolle i den oxidative metabolisme af indinavir.
In vitro studies with human liver microsomes indicated that CYP3A4 is the only P450 isozyme that plays a major role in the oxidative metabolism of indinavir.
In vitro undersøgelser som anvendte humane levermikrosomer indikerer at aprepitant hovedsagelig metaboliseres via CYP3A4 og muligvis med mindre deltagelse via CYP1A2 og CYP2C19.
In vitro studies using human liver microsomes indicate that aprepitant is metabolised primarily by CYP3A4 and potentially with minor contribution by CYP1A2 and CYP2C19.
In vitro undersøgelser til evaluering af den procentvise genfinding af den samlede dosis givet gennem en nasogastrisk, nasojejunal eller gastrostomisonde påviste, at dosis genfundet var > 99 % for doser > 1 ml og 70 % for en dosis på 0,5 ml.
In vitro studies evaluating the percent recovery of total dose delivered with nasogastric, nasojejunal or gastrostomy tubes demonstrated the percent of dose recovered was > 99% for doses > 1 ml and 70% for a 0.5 ml dose.
In vitro undersøgelser viser, at caspofungin ikke hæmmer cytokrom P450 enzymer 1A2, 2A6, 2C9, 2C19, 2D6 eller 3A4.
In vitro studies show that caspofungin is not an inhibitor of cytochrome P450 enzymes 1A2, 2A6, 2C9, 2C19, 2D6 or 3A4.
In vitro undersøgelser viste, at levetiracetam og dets primære metabolit ikke hæmmer de vigtigste human lever cytochrom P450 isoformer (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 og 1A2), glucuronyltransferase (UGT1A1 og UGT1A6) og epoxid hydroxylase aktiviteter.
In vitro, levetiracetam and its primary metabolite have been shown not to inhibit the major human liver cytochrome P450 isoforms (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 and 1A2), glucuronyl transferase (UGT1A1 AND UGT1A6) and epoxide hydroxylase activities.
In vitro undersøgelser, som anvendte humane levermikrosomer, indikerer at aprepitant hovedsageligt metaboliseres gennem CYP3A4 og muligvis med mindre deltagelse via CYP1A2 og CYP2C19.
In vitro studies using human liver microsomes indicate that aprepitant is metabolised primarily by CYP3A4 and potentially with minor contribution by CYP1A2 and CYP2C19.
In vitro undersøgelser, som anvendte humane levermikrosomer, indikerer, at aprepitant hovedsagelig metaboliseres via CYP3A4 og muligvis med mindre deltagelse via CYP1A2 og CYP2C19.
In vitro studies using human liver microsomes indicate that aprepitant is metabolised primarily by CYP3A4 and potentially with minor contribution by CYP1A2 and CYP2C19.
In vitro var blod-plasma-koncentrationsforholdet for lenvatinib i intervallet fra 0,589 til 0,608 (0,1- 10 μg/ml, mesilat).
In vitro, the lenvatinib blood-to-plasma concentration ratio ranged from 0.589 to 0.608 (0.1 – 10 μg/mL, mesilate).
In vitro var lenvatinib-blod-til-plasma-koncentrationsforholdet i intervallet fra 0,589 til 0,608 (0,1 – 10 μg/ml, mesilat).
In vitro, the lenvatinib blood-to-plasma concentration ratio ranged from 0.589 to 0.608 (0.1 – 10 μg/mL, mesilate).
In vitro var procentdelen bundet til rottealbumin, humant albumin og humant serum, henholdsvis 98,4%, 95,4% og 99,1%.
In vitro, the percent bound to rat albumin, human albumin and human serum was 98.4%, 95.4% and 99.1%, respectively.
In vitro viser tacrolimus en hæmmende effekt på P-gp, som svarer til effekten af itraconazol og ciclosporin.
Tacrolimus has been found in vitro to have a similar level of inhibitory effect on P-gp as that seen with itraconazole and cyclosporine.
In vitro, var brivaracetam ikke inhibitor af CYP 1A2, 2A6, 2B6, 2C8, 2C9, 2D6, 3A4 eller transporterne P-gb, BCRP, BSEP, MRP2, MATE-K, MATE-1, OATP1B1, OATP1B3, OAT1 og
In vitro, brivaracetam was not an inhibitor of the CYP1A2, 2A6, 2B6, 2C8, 2C9, 2D6, 3A4, or the transporters P-gp, BCRP, BSEP MRP2, MATE-K, MATE-1, OATP1B1, OATP1B3, OAT1 and
In vitro- data påviste, at bosentan ikke havde nogen relevant inhiberende virkning på de CYP- isoenzymer, som blev testet (CYP1A2, 2A6, 2B6, 2C8, 2C9, 2D6, 2E1 og 3A4).
In vitro data demonstrated that bosentan had no relevant inhibitory effect on the CYP isoenzymes tested (CYP1A2, 2A6, 2B6, 2C8, 2C9, 2D6, 2E1, 3A4).
In vitro- erytrocytkoncentrationerne af 14C-mirabegron var ca. dobbelt så høje som i plasma.
In vitro erythrocyte concentrations of 14C-mirabegron were about 2-fold higher than in plasma.
In vitro- forsøg har påvist, at indacaterol har flere gange større agonistaktivitet på beta2-receptorer sammenlignet med beta1- og beta3-receptorer.
In vitro studies have shown that indacaterol has multi-fold greater agonist activity at beta2-receptors compared to beta1 and beta3-receptors.
In vitro- forsøg indikerer, at telavancin ikke vil påvirke clearance af lægemidler, som metaboliseres af CYP isoformer 1A2, 2C9, 2C19 og 2D6.
In vitro experiments indicate that telavancin will not affect the clearance of medicinal products metabolised by CYP isoforms 1A2, 2C9, 2C19 and 2D6.
In vitro- hjertesikkerhedsstudier viste et præklinisk signal for QT-forlængelse baseret på blokering af hERG- kanalen og forlængelse af aktionspotentialets varighed i isolerede kaninhjerter med nilotinib.
In vitro cardiac safety studies demonstrated a preclinical signal for QT prolongation, based upon block of hERG currents and prolongation of the action potential duration in isolated rabbit hearts by nilotinib.
In vitro- metabolismestudier har tydet på, at CYP3A4 og i mindre grad CYP2D6 og CYP2C9 er involveret i netupitants metabolisme.
In vitro metabolism studies have suggested that CYP3A4 and, to a lesser extent, CYP2D6 and CYP2C9 are involved in the metabolism of netupitant.
In vitro- og in vivi-studier på mennesker tyder på, at amifamdiprin metaboliseres til en enkelt primær 3-N-acetyleret amifamdiprinmetabolit.
In vitro and in vivo studies in humans indicate that amifampridine is metabolised to a single major 3- N-acetylated amifampridine metabolite.
In vitro- og in vivo- forsøg har vist, at meloxicam hæmmer cyclooxygenase-2 (COX-2) i højere grad end cyclooxygenase- 1 (COX-1).
In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).
In vitro- og in vivo- undersøgelser viste, at meloxicam hæmmer cyklooxygenase-2 (COX-2) i større grad end cyklooxygenase-1 (COX-1).
In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).
In vitro- og in vivo-studier har til dato ikke påvist nogen aktivitet med hensyn til den primære metabolit (5-carboxy-pirfenidon), selv ved koncentrationer eller doser, som er langt over dem, der associeres med pirfenidons egen aktivitet.
In vitro and in vivo studies to date have not detected any activity of the major metabolite (5-carboxy-pirfenidone), even at concentrations or doses greatly above those associated with activity of pirfenidone itself.
In vitro- og in vivo-studier har vist, at meloxicam i højere grad hæmmer cyclooxygenase-2 (COX-2) end cyclooxygenase-1 (COX-1).
In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).
In vitro- og in vivo-studier har vist, at østrogener delvist metaboliseres af CYP-enzymer, herunder CYP3A4.
In vitro and in vivo studies have shown that oestrogens are partially metabolized by cytochrome P450 enzymes, including CYP3A4.
In vitro- studier indikerer, at pemetrexed udskilles ved aktivt sekretion via OAT3 (organisk aniontransporter).
In vitro studies indicate that pemetrexed is actively secreted by OAT3 (organic anion transporter.
In vitro- studier med humane levermikrosomer har vist, at paliperidon ikke væsentligt hæmmer metaboliseringen af lægemidler, som metaboliseres af cytokrom P450-isozymer, herunder CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4 og CYP3A5.
In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of medicines metabolised by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5.
In vitro- undersøgelser har indikeret, at indacaterol har en ubetydeligt mulighed til at forårsage metaboliske interaktioner med lægemidler ved de systemiske eksponeringsniveauer opnået i klinisk praksis.
In vitro investigations have indicated that indacaterol has negligible potential to cause metabolic interactions with medicinal products at the systemic exposure levels achieved in clinical practice.
In vitro- undersøgelser har vist, at laropiprants acylglucuronidkonjugat havde mindst 65 gange reduceret affinitet til DP1 i sammenligning med laropiprant; dette forventes derfor ikke at bidrage til laropiprants totale DP1-aktivitet.
In vitro studies have shown that the acyl glucuronide conjugate of laropiprant had at least a 65-fold reduced affinity for DP1 as compared to laropiprant; thus, it is not expected to contribute to the overall DP1 activity of laropiprant.
In vitro--undersøgelser har vist, at rosiglitazon primært metaboliseres af CYP2C8, med CYP2C9 som en mindre metaboliseringsvej.
In vitro studies demonstrate that rosiglitazone is predominantly metabolised by CYP2C8, with CYP2C9 as only a minor pathway.
In vitro-aktivitet mod Dichelobactor nodosus (virulent), som er det bakterielle patogen, der oftest forbindes med smitsom pododermatitis (klovsyge), er påvist hos får.
In vitro activity against Dichelobacter nodosus (vir), the bacterial pathogen most commonly associated with infectious pododermatitis (foot rot) in sheep has been demonstrated.
In vitro-aktivitet over for følgende patogener er vist, men den kliniske betydning er ukendt:
In vitro activity against the following pathogens has been shown, but the clinical significance is unknown:
In vitro-binding af lenvatinib til humane plasmaproteiner er høj og i intervallet fra 98 % til 99 % (0,3 - 30 μg/ml, mesilat).
In vitro binding of lenvatinib to human plasma proteins is high and ranged from 98% to 99% (0.3 - 30 μg/mL, mesilate).
In vitro-binding af lenvatinib til humane plasmaproteiner er høj og i intervallet fra 98 % til 99 % (0,3-30 μg/ml, mesilat).
In vitro binding of lenvatinib to human plasma proteins is high and ranged from 98% to 99% (0.3 - 30 μg/mL, mesilate).
In vitro-data
In vitro data
In vitro-data indikerer, at enzalutamid ikke er substrat for OATP1B1, OATP1B3 eller OCT1, og N- desmethyl-enzalutamid er ikke substrat for P-gp eller BCRP.
In vitro data indicate that enzalutamide is not a substrate for OATP1B1, OATP1B3, or OCT1; and N-desmethyl enzalutamide is not a substrate for P-gp or BCRP.
In vitro-data indikerer, at følgende arter ikke er følsomme over for ceftolozan/tazobactam:
In vitro data indicate that the following species are not susceptible to ceftolozane/tazobactam:
In vitro-data indikerer, at gefitinib er et substrat for membrantransportproteinet Pgp.
In vitro data indicate that gefitinib is a substrate for the membrane transport protein Pgp.
In vitro-data indikerer, at regorafenib metaboliseres af cytokrom CYP3A4 og af uridindiphosphat-glucuronosyltransferase UGT1A9.
In vitro data indicate that regorafenib is metabolized by cytochrome CYP3A4 and uridine diphosphate glucuronosyl transferase UGT1A9.
In vitro-data indikerer, at repaglinid bliver metaboliseret fortrinsvis af CYP2C8 men også af CYP3A4.
In vitro data indicate that repaglinide is metabolised predominantly by CYP2C8, but also by CYP3A4.
In vitro-data indikerer, at størstedelen af NS5A-RAV’er med resistens over for ledipasvir og daclatasvir, forblev følsomme for velpatasvir.
In vitro data suggests that the majority of NS5A RAVs that confer resistance to ledipasvir and daclatasvir remained susceptible to velpatasvir.
In vitro-data påviste, at bosentan ikke havde nogen relevant inhiberende virkning på de CYP- isoenzymer, som blev testet (CYP1A2, 2A6, 2B6, 2C8, 2C9, 2D6, 2E1 og 3A4).
In vitro data demonstrated that bosentan had no relevant inhibitory effect on the CYP isoenzymes tested (CYP1A2, 2A6, 2B6, 2C8, 2C9, 2D6, 2E1, 3A4).
In vitro-data tyder på, at brivaracetam har et lavt interaktionspotentiale.
In vitro data suggest that brivaracetam has a low interaction potential.
In vitro-data tyder på, at den primære metaboliseringsvej for empagliflozin hos mennesker er glucuronidering via uridin 5'-diphosphoglucuronosyltransferase UGT1A3, UGT1A8, UGT1A9 og UGT2B7.
In vitro data suggest that the primary route of metabolism of empagliflozin in humans is glucuronidation by uridine 5'-diphosphoglucuronosyltransferases UGT1A3, UGT1A8, UGT1A9, and UGT2B7.
In vitro-data tyder på, at den primære metaboliseringsvej for empagliflozin hos mennesker er glukuronidering via uridin 5'-difosfoglukuronosyltransferase UGT1A3, UGT1A8, UGT1A9 og UGT2B7.
In vitro data suggest that the primary route of metabolism of empagliflozin in humans is glucuronidation by uridine 5'-diphosphoglucuronosyltransferases UGT1A3, UGT1A8, UGT1A9, and UGT2B7.
In vitro-data tyder på, at potentialet for farmakokinetisk lægemiddelinteraktion relateret til CYP- interaktion og proteinbinding er lavt for både liraglutid og insulin degludec.
In vitro data suggest that the potential for pharmacokinetic drug interactions related to CYP interaction and protein binding is low for both liraglutide and insulin degludec.
In vitro-data tyder på, at ulipristalacetat kan hæmme brystcancerresistensprotein (BCRP)- transportører i tarmsystemet.
In vitro data indicate that ulipristal acetate may be an inhibitor of BCRP (Breast Cancer Resistance Protein) transporters at the intestinal level.
In vitro-data viser, at CYP2C9, CYP2C19 og CYP3A4 kan katalysere dannelsen af desmethylmetabolitten, men det primært involverede isoenzym er ikke blevet fastlagt in vivo.
In vitro data show that CYP2C9, CYP2C19 and CYP3A4 are capable of catalysing the formation of the O-desmethyl metabolite but the main contributing isoenzyme has not been confirmed in vivo.
In vitro-data viser, at CYP2C9, CYP2C19 og CYP3A4 kan katalysere dannelsen af desmethylmetabolitten, men det primært involverede isoenzym er ikke blevet fastlagt in vivo.
In vitro data show that CYP2C9, CYP2C19 and CYP3A4 are capable of catalysing the formation of the O-desmethyl metabolite but the main contributing isoenzyme has not been confirmed in vivo..
In vitro-data viser, at CYP2C9, CYP2C19 og CYP3A4 kan katalysere dannelsen af O-desmethylmetabolitten.
In vitro data show that CYP2C9, CYP2C19 and CYP3A4 are capable of catalysing the formation of the O- desmethyl metabolite.
In vitro-data viser, at fesoterodins aktive metabolit ikke hæmmer CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 eller 3A4 eller inducerer CYP1A2, 2B6, 2C9, 2C19 eller 3A4 ved klinisk relevante plasma- koncentrationer.
In vitro data demonstrate that the active metabolite of fesoterodine does not inhibit CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, or 3A4, or induce CYP1A2, 2B6, 2C9, 2C19, or 3A4 at clinically relevant plasma concentrations.
In vitro-data viser, at ketoconazol hæmmer CYP1A2 og ikke hæmmer CYP 2A6 og 2E1 i signifikant grad.
In vitro data indicate that ketoconazole is an inhibitor of CYP1A2 and does not significantly inhibit CYP 2A6 and 2E1.
In vitro-data viser, at selexipag kan være en induktor af både CYP3A4 og CYP2C9 i tarmen.
In vitro data indicate that selexipag could be an inducer of both CYP3A4 and CYP2C9 in the intestine.
In vitro-data viste også, at olaparib ikke er et substrat for OATP1B1-, OATP1B3-, OCT1-, BCRP- eller MRP2 og ikke en inhibitor af OATP1B3, OAT1 eller MRP2.
In vitro data also show that olaparib is not a substrate for OATP1B1, OATP1B3, OCT1, BCRP or MRP2 and not an inhibitor of OATP1B3, OAT1 or MRP2.
In vitro-eksperimenter indikerer, at rilpivirinhydrochlorid primært gennemgår oxidativ metabolisme medieret af cytokrom P450 (CYP)3A-systemet.
In vitro experiments indicate that rilpivirine hydrochloride primarily undergoes oxidative metabolism mediated by the cytochrome P450 (CYP)3A system.
In vitro-eksperimenter viser, at lumacaftor er et substrat for brystcancerresistensprotein (BCRP).
In vitro experiments show that lumacaftor is a substrate for Breast Cancer Resistance Protein (BCRP).
In vitro-forsøg har påvist, at indacaterol, som er en langtidsvirkende beta2-adrenerg agonist, har mere end 24 gange større agonistaktivitet på beta2-receptorer sammenlignet med beta1-receptorer og 20 gange større agonistaktivitet sammenlignet med beta3-receptorer.
In vitro studies have shown that indacaterol, a long-acting beta2-adrenergic agonist, has more than 24-fold greater agonist activity at beta2-receptors compared to beta1-receptors and 20-fold greater agonist activity compared to beta3- receptors.
In vitro-forsøg har vist, at hæmning af nøgletransportører, der er forbundet med lægemiddelfjernelse i nyren (organisk aniontransporterende polypeptid-1B1 (OATP1B1), OATP1B3, organisk aniontransportør-1 (OAT1), OAT3 og organisk kationisk transportør-2 (OCT2)) ved eksponeringer efter inhalation af 240 mg levofloxacin to gange dagligt, er lav.
In vitro studies demonstrated that inhibition of the key transporters associated with drug disposition in the kidney (organic anion-transporting polypeptide-1B1 (OATP1B1), OATP1B3, organic anion transporter-1 (OAT1), OAT3 and organic cationic transporter-2 (OCT2)) at exposures following inhalation of 240 mg levofloxacin twice daily is low.
In vitro-forsøg har vist, at nalmefen er en selektiv opioidreceptorligand med antagonistvirkning på μ- og δ-receptorerne og partiel agonistaktivitet på κ-receptoren.
In vitro studies have demonstrated that nalmefene is a selective opioid receptor ligand with antagonist activity at the μ and δ receptors and partial agonist activity at the κ receptor.
In vitro-forsøg med menneske-, hunde-, muse- og rotteplasma viste en høj plasmaproteinbinding (> 99,5 %), overvejende til albumin og α-1-syreglycoprotein.
In vitro studies in human, dog, mouse and rat plasma showed a high plasma protein binding (> 99.5 %), mainly to albumin and α-1-acid glycoprotein.
In vitro-forsøg og dyremodeller har vist, at abatacept modulerer det T-lymfocytafhængige antistofrespons og inflammation.
Studies in vitro and in animal models demonstrate that abatacept modulates T lymphocyte-dependent antibody responses and inflammation.
In vitro-forsøg tyder på, at pazopanib er et P- gp-substrat og et BCRP-substrat.
In vitro studies suggest that pazopanib is a substrate for P-gp and BCRP.
In vitro-histaminfrigivelsen fra basofile celler, som blev isoleret fra forsøgspersoner behandlet med Xolair, reduceret med cirka 90 % efter stimulering med et allergen sammenlignet med værdier før behandling.
The in vitro histamine release from basophils isolated from Xolair-treated subjects was reduced by approximately 90% following stimulation with an allergen compared to pre-treatment values.
In vitro-interaktionsstudier, som havde til formål at vurdere den potentielle inhibitoriske virkning på transportører, konkluderede, at der ikke var nogen klinisk relevante virkninger, bortset fra OAT3.
In vitro, interaction studies to determine the potential inhibitory effects on transporters concluded that there were no clinically relevant effects, except for OAT3.
In vitro-interaktionsundersøgelser for transportmekanismer
In vitro transporter interaction studies
In vitro-plasmaproteinbindingen for ambrisentan var gennemsnitligt 98,8 % og uafhængig af koncentrationen i intervallet 0,2 - 20 mikrogram/ml.
The in vitro plasma protein binding of ambrisentan was, on average, 98.8% and independent of concentration over the range of 0.2 – 20 microgram/ml.
In vitro-potentialet for lægemiddelinteraktioner mellem sofosbuvir/velpatasvir
In vitro potential for sofosbuvir/velpatasvir drug-drug interations
In vitro-proteinbinding
In vitro protein binding
In vitro-proteinbinding af cidofovir til plasma eller serumprotein var 10 % eller mindre i cidofovirs koncentrationsområde fra 0,25 til 25 µg/ml.
In vitro protein binding of cidofovir to plasma or serum protein was 10% or less over the cidofovir concentration range 0.25 to 25 µg/ml.
In vitro-proteinbindingen af olaparib ved plasmakoncentrationer opnået efter dosering ved 400 mg to gange dagligt er ~82 %.
The in vitro protein binding of olaparib at plasma concentrations achieved following dosing at 400 mg twice daily is ~82%.
In vitro-proteinbindingen er ca.
The in vitro protein binding is approximately 60% to 70%.
In vitro-prøver indikerer, at graden og varigheden af denne interferens afhænger af en række faktorer, som f.eks. doseringen af hydroxocobalamin, analyten, analytkoncentrationen, metoden, analysatoren, koncentrationen af forskellige cobalamin-(III)-ioner, herunder cyanocobalamin, og til dels tiden fra prøvetagning til faktisk måling.
In vitro tests indicate that the extent and duration of the interference is dependant on numerous factors such as the dose of hydroxocobalamin, analyte, analyte concentration, methodology, analyser, concentrations of cobalamins-(III) including cyanocobalamin and partially the time between sampling and measurement.
In vitro-resultater viser, at forskellige CYP-isoformer er i stand til at katalysere rotigotins N-dealkylering.
In vitro results indicate that different CYP isoforms are able to catalyse the N-dealkylation of rotigotine.
In vitro-studier har afgjort, at hverken tenofovirdisoproxilfumarat eller tenofovir er substrater for CYP-enzymerne.
In vitro studies have determined that neither tenofovir disoproxil fumarate nor tenofovir are substrates for the CYP enzymes.
In vitro-studier har afgjort, at hverken tenofovirdisoproxilfumarat eller tenofovir er substrater for CYP450-enzymerne.
In vitro studies have determined that neither tenofovir disoproxil fumarate nor tenofovir are substrates for the CYP450 enzymes.
In vitro-studier har endvidere vist, at eltrombopag er et substrat for, og en hæmmer af, det brystcancer-resistente protein (BCRP).
In vitro studies also demonstrated that eltrombopag is a breast cancer resistance protein (BCRP) substrate and inhibitor.
In vitro-studier har vist at hverken oseltamivir eller den aktive metabolit er substrat for eller hæmmer af CYP- isoformer.
In vitro studies demonstrated that neither oseltamivir nor the active metabolite is a substrate for, or an inhibitor of, the major cytochrome P450 isoforms.